Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Return to: PBR Home | Contract Research & Services
Today in Contract Research & Services

Contract Research & Services

AstraZeneca sells US rights to gout drug Zurampic to Ironwood Pharmaceuticals AstraZeneca is selling the US rights to its gout treatment Zurampic (lesinurad) to Ironwood Pharmaceuticals. Contract Research & Services > Contract Services > News

Latest Contract Research & Services News by Sector

Select a sector from the list or browse by sector below:

Clinical Trials

Concert Pharmaceuticals unveils positive data from multiple dose phase 1 trial of CTP-656
Concert Pharmaceuticals announced positive topline data from a Phase 1 multiple ascending dose clinical trial of CTP-656.
Contract Research & Services > Clinical Trials > News
Theratechnologies unveils completion of enrollment for phase III Ibalizumab trial
Theratechnologies has been notified by its partner, TaiMed Biologics, Inc., that the enrollment for the Phase III study of ibalizumab, in combination with optimized background regimen (patients' current therapy), for patients infected with multi-drug resistant HIV-1 has been completed as of April 27, 2016.
Contract Research & Services > Clinical Trials > News

Contract Research

AbbVie forms two oncology-focused collaborations with CytomX and argenx
By PBR Staff Writer
Research-based biopharmaceutical firm AbbVie has entered into two oncology-focused collaborations with CytomX Therapeutics and argenx.
Contract Research & Services > Contract Research > News
Basilea signs deal with BARDA for phase 3 development of ceftobiprole antibiotic
By PBR Staff Writer
Basilea Pharmaceutica has signed an agreement worth $100m with the US Department of Health for the clinical phase 3 development of ceftobiprole antibiotic.
Contract Research & Services > Contract Research > News

Contract Services

BioQ Pharma expands US license and supply deal with Sandoz
BioQ Pharma has expanded its license and supply agreement with Sandoz, a division of Novartis, under which Sandoz now has the right to exclusively market an additional ready‐to‐use BioQ Pharma infusion pharmaceutical in the US.
Contract Research & Services > Contract Services > News
AstraZeneca sells US rights to gout drug Zurampic to Ironwood Pharmaceuticals
By PBR Staff Writer
AstraZeneca is selling the US rights to its gout treatment Zurampic (lesinurad) to Ironwood Pharmaceuticals.
Contract Research & Services > Contract Services > News